【小摩：升亚盛医药(06855.HK)目标价至93港元 评级“增持”】智通财经APP获悉，摩根大通发布研报称，亚盛医药(06855.HK)股价年内累涨约83%，与恒生医疗保健指数的强劲表现(年内累升约78%)同步。该行在最近举行的中美生物技术论坛与管理层讨论后，并考虑公司产品管线的最新进展，小摩更新了模型。小摩纳入对产品更乐观的销售预估，将亚盛医药目标价由原先52港元大幅上调79%至93港元;维持增持评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.